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Abstract:
Using a case study ofAcclarent, a medical device compaoy, this paper attempts to
propose a framework to further illustrate the process of open innovation in the medical
device industry. We examined five elements in the mechanism ofthe open innovation
process. Our paper shows how the success of Acclarent--a medical device start-up-
depends on effective management ofthe flow of knowledge to satisfy uomet needs,
while integrating in-depth knowledge of FDA regolations aod third-party payers'
reimbursement policies into the product innovation process.
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Introduction
The concept of open innovation manifests the importance of firms employing "external
ideas as well as internal ideas, and internal and external patha to market" [Chesbrough
(2003a)] as they progress with their technology development. The underlying assumption
of open innovation is the ''mobility ofknowledge workers" and the availability of capital
which enable the generation of innovative ideas outside ofthe "silos" of corporate
research labs [Chesbrough (2003b)].
The power of open innovation lies in the fact that knowledge created through such an
open mindset and corporate policy can be reused and it can lead to increasing returns
[Arthur (1996)]. Moreover, both the breadth and depth ofthe collective knowledge can
surpass the knowledge contribution of an individual provider [Chesbrough & Appleyard
(2007)].
Although the idea of open innovation paves an alternative path to the advancement of
technology, theoretical discussions are still insufficient to expound the mechanism of
open innovation. Open innovation contributes to broadening the "realm" for knowledge
creation by focusing on "different sources of external knowledge" and the balancing
role of both external and internal sources ofknowledge [van de Vrande eta/. (2010)
]. Nevertheless, the theory does not provide us with a clear guidance on how new
knowledge, the core ofinnovation, is constructed. In this paper, using the case of
Acclarent, we plan to contribute to existing theories through an in-depth examination on
"how" knowledge is created or recreated through such a process.
Theoretical Background
West and Bogers [2011] conducted an extensive literature review on open innovation
research and they developed a four-phase model for inbound open innovation to
categorize prior studies in open innovation. These four phases include: "obtaining,
integrating and commercializing external innovation, as well as work on nonreciprocal
innovation flows." For the purpose ofthis paper, we only allude literature related to the
first phase in their model.
In terms of obtaining external innovation, stodies have examined external stakeholders,
e.g. [Iii eta/. (2010); Tether and Tajar (2008)], suppliers [Li and Vanhaverbeke (2009);
Schiele (2010)], competitors [Lim eta/. (2010)], or universities [Cassiman eta/.
(2010); Fabrizio (2009)], as well as market-feedback [Dodgson eta/. (2006)], networks
[Vanhaverbeke (2006); Zeng eta/. (2010)], and communities [Starn (2009); Janzik
(2010)] as source of external knowledge. In addition, Tortoriello and Krackhardt [2010]
demonstrated that the nature of relationship between a firm and an external stakeholder
may determine the effectiveness of the search for external innovation. Moreover, there
is also an increasing amount ofresearch scrutinizing the role of third party actors in
enabling external innovation, e.g. [Jeppesen and Lakhani (2010); Mortara eta/. (2010)].
In addition to stodies on obtaining external innovation, other research investigating
different aspects in open innovation includes: analyzing firms adopting an outside-in
(versus an inside-out) approach of open innovation, e.g. [Lichtenthaler and Ernst (2007);
Witzeman eta/. (2006)], examining small and medium-sized enterprises (SMEs) rather
than the traditionally large, multinational enterprises, e.g. [DeJong and Marsili (2006);
Massa and Testa (2008); Ndou eta/. (2011)]; exploring firms' cultural dimensions of
implementing open innovation [Herzog and Leker (2010)], stodying different types of
alliance strategies to maximize startup firms' innovation performance [Neyens eta/.
(2010)], and incorporating analysis ofuser innovation, customer interaction, online
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community, and alliance networks in the existing literature,e.g. [Hienerth (2006); Lett!
(2007); Spaeth eta/. (2010), and Van Rijswijk eta/. (2008), Weber eta/. (2012)].
While existing research on open innovation has certainly expanded the scope of the
original concept and enlightened us on various open channels of sources of ideas,
there is still a lack of attention on the process ofknowledge (re)creation, which is the
underpinning of innovation.

Our proposed model in investigating how innovative knowledge is generated through
interaction of both external and internal sources is meant to establish a framework of
linking macro and micro levels of analysis regarding knowledge exchange and flow,
thereby enhancing the value of the open innovation paradigm.
Using a case study of Acclarent, a medical device company, this paper attempts to
illustrate how the process of open innovation is implemented in the medical device
indus(ry, which can shed some light to the mechanism of open innovation.
In our proposed framework, we focus on five essential elements to capture the
mechanism of innovation in medical device businesses. These five elements include:
sources of ideas, the interrelationship (quality of relationship) between innovators and
the sources of ideas, types ofknowledge, characteristics of knowledge, and path for
knowledge acquisition. We first give a brief introduction of the case, then illustrate the
five elements in the following sections. Data are obtained through both face-to-face
interviews and secondary resources.

Research Method
Since previous studies examining open innovation in the medical device indus(ry are
scarce, we employed both primary and secondary research to obtain first-hand data as
well as background information on medical device companies and the indus(ry. The
medical device companies we selected for interview are from the MDR Web site. We
used locations, annual revenue, and patents as major criteria for determining medical
companies in our sample. AJ; a prelimioary research, we employ a case study method in
this paper to have an in-depth understanding of the phenomena. Our literature review
on medical device indus(ry indicated that many medical device companies center in the
Silicon Valley area.
Acclarent was chosen because it was located in Menlo Park, a hub for many medical
device companies in Silicon Valley. The company had 16 active patents in 2009. In our
in-depth interview with Bill Facteau, CEO of the company, he provided us with ample
data on the company's innovation procedures and practices, and challenges the company
faced in developing new products. In addition, we were able to find valuable secondary
information from the book related to the process of innovating medical technologies,
co-authored by Joshua Makower, founder of Acclarent, which offered us insightful
details on how the idea of the Acclarent 's Balloon Sinuplasty devices was formed. The
combined interviews, case studies, and archival research thus presented us a much more
clear and affiueot resource on the innovation of Acclarent's Balloon Sinuplasty product
as well as key issues concerning innovation in the medical device indus(ry. The rich
information we collected rendered Acclarent worthy for a case study.

The Case of Acclarent

Backgr ound
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device companies to select a path where clinical trials are not required in inventing new
products. Consequently, further investigations ofhow FDA's regulations facilitate or
hinder innovation in the medical device industry (especially small firms) are called for.
For medial device companies, obtaining adequate coverage and reimbursement from
third-party payers such as private health insurance companies, Medicare, and Medicaid
for all or part of the costs and fees associated with using medical devices, is critical for
medical device product acceptance and widespread adoption in the marketplace [Risk
Factors]. Reimbursement constitutes part of the revenue of medical device companies
and may be a crucial source of funding for continuous innovation in these companies.
Acclarent claimed that approximately 15 third-party payers do not currently cover or
reimburse sinus procedure performed with its Balloon Sinuplasty devices because they
believe such devices is new and investigational [Risk Factors]. These private payers have
generally required using a separate billing code that is unique for Balloon Sinuplasty
[Risk Factors]. Nevertheless, the fact that the Balloon Sinuplasty instrument is considered
a "tool" rather than a "procedure" allows Acclarent to get reimbursement from existing
Category I Current Procedure Terminology, or CPT, codes relating to the various sinuses
treated using FESS procedure. "These codes do not currently distinguish between FESS
performed with Balloon Sinuplasty devices and traditional instruments" [Risk Factors].
In addition to the reimbursement from third-party payers, Acclarent had 6% of its
revenue from international sales of its Balloon Sinuplasty devices by 2008 [Risk Factors].
Acclarent' s case suggests that the third-party reimbursement policies and the medical
coding system may siguificantly impact the profits ofmedical device companies.
As a result, the structure ofthe medical codes and payment guidelines can be vital
affecting the medical device company's innovation process. To determine ifthe Balloon
Sinuplasty team should proceed further with the invention, Acclarent hired a professional
reimbursement consulting finn to evaluate whether the use oftheir Balloon Sinuplasty
devices could fit within the existing FESS codes. The team's idea was able to be carried
out due to the positive feedback they received from the consulting finn as well as a legal/
reimbursement expert [Zenios eta/. (2010)].
Acclarent's case also reveals that there is complex knowledge regarding how to
"categorize" the nature of an innovative device since different categorization could
influence the pathway to innovation and the potential development ofthe end product.
Future research should further investigate how reimbursement criteria, policies, and
coding systems may have an effect on a medical device company's innovation process.
Discussion and conclusion
Most of the existing literatore in open innovation tends to focus on high tech companies
when investigating factors related to open innovation, this paper adds to prior research
in this field by extending the theory to the realm ofmedical industry. Acclarent's
case indicates that open innovation is one ofthe essential elements for medical device
companies to explore the unmet needs in the market thereby sustaining its innovative
capability in a highly competitive industry. We examined the five elements in the
mechanism ofthe open innovation process. "Fulfilling the unmet needs" is necessary but
not sufficient for an innovative product to be successful in its commercialization. Since
medical device companies are regulated by FDA, familiarity with FDA's regulations
to obtain clearance for product pre-market approval is critical in determining whether
the innovative product can be commercialized. In addition, revenue of medical device
companies depends, to a large degree, on third-party payers' reimbursement. Therefore, a
thorough understanding ofthird-party payers' reimbursement criteria and medical codes
system is essential for medical device firms tu be profitable.
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